Background
The prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a growing concern among people with HIV (PWH), driven in part by the rising prevalence of obesity. A recent study demonstrated a MASLD prevalence of 52% and an advanced fibrosis prevalence of 15% in a cohort of PWH (Gawrieh 2024). Excess visceral abdominal fat (EVAF) is a significant risk factor for MASLD in the general population. We sought to investigate how EVAF impacts hepatic steatosis (HS) and hepatic fibrosis (HF) in PWH, and if EVAF is associated with HS in PWH with normal BMI.
Methods
The Visceral Adiposity Measurement and Observations Study (VAMOS) is a multi-center, observational study in PWH with long-term viral suppression and BMI 20-40 kg/m2. Participants completed a single-slice abdominal computed tomography scan at the L4-L5 level to quantify visceral adipose tissue (VAT). EVAF was defined as a VAT area ≥130 cm2. Vibration-controlled transient elastography assessed HS and HF prevalence, measured by controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), respectively. HS and HF were defined as CAP>238 dB/m and LSM>7.0 kPa respectively. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression, with HS as the outcome, to assess associations with VAT area and waist circumference (WC) . Relationships with HS and HF were assessed by Spearman correlation.
Results
Among the 170 participants, 54% had HS and 17% had HF. Participants with EVAF had 3 times the odds of HS compared to those without EVAF (OR=3.06; 95% CI, 1.62-5.80). Similarly, participants with elevated WC (>94 cm males; >95 cm females) had higher odds of HS than those with normal WC (OR=4.36; 95% CI, 2.23-8.53). HS moderately correlated with VAT area (ρ=0.42; p<0.0001), WC (ρ=0.51; p<0.0001), and BMI (ρ=0.48; p<0.0001). Despite this significant relationship with BMI, HS was still seen in 33% of PWH with normal BMI (<25 kg/m2, “normal-weight HS”). Of participants with normal-weight HS, 75% had EVAF . There was a weak correlation observed between HF and VAT (ρ=0.16, p=0.04) and between HF and WC (ρ=0.27, p=0.0005).
Conclusions
HS and HF are common among PWH , particularly among PWH with EVAF or elevated WC. Strikingly, normal-weight HS was seen in 33% of the VAMOS cohort, driven largely by the presence of EVAF. Incorporating tools to assess EVAF in clinical care, such as measuring WC, could provide critical information in identifying PWH at risk of HS.